Matinas BioPharma Holdings Inc (MTNB) USD0.0001

Sell:$1.15Buy:$1.39No change

Prices delayed by at least 15 minutes
Sell:$1.15
Buy:$1.39
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:$1.15
Buy:$1.39
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.

Objective

Key people

Jerome D. Jabbour
Chairman of the Board, President, Chief Executive Officer, Director
Keith A. Kucinski
Chief Financial Officer
Evelyn D'An
Independent Director
Keith E. Murphy
Independent Director
Edward Neugeboren
Independent Director
Robin L. Smith
Independent Director
Click to see more

Key facts

  • Shares in issue
    6.41m
  • EPIC
    MTNB
  • ISIN
    US5768103039
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $7.56m
  • Employees
    3
  • Exchange
    Nyse American LLC
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.